New data concerning treatment of urogenital cancer patients presented at annual congress of American Society of Clinical Oncology 2011
Journal Title: OncoReview - Year 2011, Vol 1, Issue 4
Abstract
INTRODUCTION: The annual congress of The American Society of Clinical Oncology took place between 03.06.2011 and 06.06.2011 in Chicago, the US.MATERIAL AND METHODS: Papers presented during ASCO are discussed in four sections: Testicular Cancer, Prostate Cancer, Kidney Cancer and Urothelial Carcinoma.RESULTS: About 160 original papers concerning urogenital cancers were surveyed. Phase III studies are discussed as well as the supplemental analyses of the phase III trials published during ASCO. A brief summary of phase I and phase II trials was also provided.Conclusion : The ASCO Annual Congress is the conclusion of the advances in the field of medical oncology.
Authors and Affiliations
Paweł Wiechno
Keywords
Related Articles
- EP ID EP53126
- DOI -
- Views 216
- Downloads 0
Irreversible tyrosine kinase inhibitors of epidermal growth factor receptors family – a new, promising therapeutic strategy
Inhibitors of tyrosine kinase residues of epidermal growth factor receptor family (ErbB) have became a treatment of choice in many tumor types. However, even in the presence of predictive factors some patients completely...
Skin of sailor: cutis rhomboidalis nuchae, actinic keratosis, squamous cell carcinoma and basal cell carcinoma. Case report
Chronic exposure to environmental ultraviolet radiation (UVR) plays a key role both in photocarcinogenesis and induction of accelerated skin ageing. Sailors commonly experience a significant number of cutaneous problems,...
The management and outcome of essential thrombocythemia in pregnancy - single-center experience
Essential thrombocythemia (ET) is a myeloproliferative neoplasm characterized by an increase in platelet (PLT > 450 000/μl) and a tendency for either thrombosis or hemorrhage. ET is often diagnosed in elderly life...
Patient with metastatic renal cell carcinoma treated successfully with pazopanib for four years.
We present a case of a patient with metastatic renal cell carcinoma who was treated with pazopanib in the first-line treatment. Although nephrectomy was not performed, there was a positive reaction to the therapy with mu...
Everolimus – effectively reverses acquired resistance on endocrine therapy of patients with advanced breast cancer. A case report
Breast cancer is the most common malignancy among women in Poland. Endocrine therapy is the first line of treatment in hormone-receptor-positive advanced breast cancer. Progression during endocrine therapy is unavoidable...